Peptide therapy for weight loss uses GLP-1 receptor agonist-class medications — such as semaglutide and the dual-agonist tirzepatide — that regulate appetite and glucose metabolism. In clinical trials these agents produced roughly 15 to 22 per cent mean body-weight reduction over 68 to 72 weeks, but they require medical supervision and carry real, well-documented side effects.
What is peptide therapy for weight loss?
Peptide therapy for weight loss refers to a specific class of injectable peptides that influence how the body regulates hunger, satiety and blood glucose. These are not the same as the reparative peptides discussed elsewhere in longevity medicine.
Peptides are short chains of amino acids that act as biological signalling molecules. The body produces many of them naturally, and the incretin hormone GLP-1 (glucagon-like peptide-1) is one. GLP-1 is released from the gut after eating and communicates with receptors in the brain that govern appetite. The medications used for weight management are engineered analogues of these hormones, designed to remain active in the body far longer than the natural version. They work by dampening hunger signals, slowing gastric emptying so meals feel more filling for longer, and improving the body’s insulin response.
It is worth being clear from the outset: these are prescription medications, not supplements, and they belong to a fast-moving area of medicine that attracts a great deal of attention. That attention is warranted by genuine efficacy data — but it also means marketing frequently outruns the evidence. We think patients are best served by understanding both.
Which peptides are actually used for weight management?
The peptides relevant to weight loss are GLP-1 receptor agonists and related metabolic agents — a distinct group from the cellular-repair peptides used in tissue recovery and longevity protocols.
The two best-evidenced agents are semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual agonist that acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Both are administered as a once-weekly subcutaneous injection and are titrated upward gradually to manage tolerability. Their mechanism is metabolic and appetite-regulating, which is why they are effective across a range of body types and are increasingly studied for conditions linked to metabolic dysfunction, not weight alone.
This is the key distinction from the peptides many people associate with regenerative clinics. Reparative peptides — the type covered in our discussion of peptide therapy’s broader role in cellular repair — are aimed at tissue healing, recovery and cellular signalling. They are a different tool for a different purpose. Conflating the two is one of the most common sources of confusion we encounter, and it matters clinically, because candidacy, monitoring and safety considerations differ substantially between the groups.
How effective is peptide therapy for weight loss?
The efficacy data for GLP-1-class peptides is among the strongest in the weight-management field, drawn from large randomised controlled trials.
In the STEP 1 trial published in the New England Journal of Medicine, semaglutide 2.4 mg combined with lifestyle intervention produced a mean body-weight reduction of 14.9 per cent at 68 weeks, compared with 2.4 per cent on placebo, in nearly 2,000 adults with overweight or obesity (Wilding et al., NEJM, 2021). For tirzepatide, the SURMOUNT-1 trial reported mean reductions of 16.0 per cent, 21.4 per cent and 22.5 per cent at the 5 mg, 10 mg and 15 mg doses respectively over 72 weeks, against 2.4 per cent on placebo (Jastreboff et al., NEJM, 2022).
Two caveats deserve emphasis. First, these results were achieved alongside dietary and lifestyle support, not in isolation. Second, the effect is treatment-dependent: trial data show that a substantial proportion of lost weight tends to return after discontinuation. Peptide therapy is therefore best understood as one component of a sustained metabolic strategy, not a short course with a permanent result.
Is peptide therapy for weight loss safe?
These medications have an established safety profile, but they carry real and common side effects, which is precisely why medical supervision is not optional.
According to the FDA prescribing information for semaglutide, 73 per cent of treated patients reported gastrointestinal adverse reactions, versus 47 per cent on placebo. The most frequent were nausea (44 per cent), vomiting (25 per cent) and diarrhoea (30 per cent) (WEGOVY Prescribing Information, FDA). Most are mild to moderate and ease as the dose is titrated, but they are not trivial. The same label notes postmarketing reports of acute kidney injury, in some cases requiring dialysis, largely in patients who became dehydrated through severe vomiting or diarrhoea.
There are also formal contraindications — including a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 — and cautions around pancreatitis, gallbladder disease and use in pregnancy. This is why a proper clinical assessment, rather than an online prescription, is the responsible starting point. Effects on lean mass during rapid weight loss are an area of active research and one reason we monitor body composition, not the scale alone.
Who is a suitable candidate?
Suitability is a clinical judgement, not a number on a chart, and weight is rarely the whole picture.
For many patients, excess weight sits alongside broader metabolic concerns — insulin resistance, elevated blood glucose, fatty liver, cardiovascular risk or the metabolic shifts that accompany hormonal change. In these cases the goal is metabolic health, and weight reduction is one lever among several. Peptide therapy can be a valuable option, but it sits within a wider toolkit that includes nutrition, physical activity, sleep, and — where appropriate — other medical approaches. It is not a substitute for those foundations, and we are cautious with anyone hoping it will be.
We also frequently speak with family members researching options on behalf of a parent, partner or adult child whose weight is affecting their health. That instinct to help is a good one. The most useful thing a family can do is encourage a proper assessment, because candidacy, dosing and monitoring are genuinely individual. What is right for one person may be inappropriate — even unsafe — for another.
How does this differ from cellular-repair peptides?
The short answer: different peptides, different targets, different reasons to use them.
Weight-management peptides act on the metabolic and appetite-regulating pathways described above. Cellular-repair peptides are used to support tissue recovery, healing and cellular signalling — the domain of recovery, injury and longevity work rather than metabolic regulation. A patient may, after assessment, be a candidate for one, both or neither. The categories are not interchangeable, and any clinic that treats them as a single “peptide” offering is glossing over a distinction that affects both outcomes and safety. Where the two overlap in a single protocol, sequencing and monitoring are decided case by case.
Metabolic Health Support at Holina Clinic
Peptide therapy is an established service at Holina Clinic, delivered within a broader regenerative and longevity medicine framework. Because GLP-1-class peptides carry real candidacy and safety considerations, we do not offer them as an off-the-shelf product. Every patient begins with an individualised clinical assessment — reviewing medical history, current medications, contraindications and metabolic markers — so that any recommendation is grounded in that person’s physiology rather than a generic template. You can read more about our peptide therapy service and the role of advanced diagnostics in shaping a protocol.
Where peptide therapy is appropriate, it is monitored over time and integrated with nutrition, activity and the other elements of a sustainable metabolic strategy — not prescribed and forgotten. Where it is not appropriate, we say so and discuss alternatives.
Care is available at both of our Thailand campuses: the Koh Phangan clinic and the Khao Yai clinic. Whether you are considering options for yourself or researching on behalf of a loved one, you are welcome to speak with our clinical team about whether an assessment makes sense for your situation.
“The efficacy data for these peptides is genuinely impressive, and it has changed the conversation around metabolic health. But the same data comes with a clear safety profile that has to be respected. Our job is not to hand out a medication — it is to work out whether it is right for the person in front of us, and then to monitor them properly. That is the difference between responsible care and a prescription pad.” — Dr. Natalie Lindemann, Clinical Director (Global), Holina Global
Frequently asked questions
Is peptide therapy for weight loss the same as Ozempic or Wegovy?
Those are brand names for semaglutide, a GLP-1 receptor agonist and one of the peptides used in this area. Tirzepatide is another. The underlying medications are the same class discussed here.
How much weight can I expect to lose?
Clinical trials reported mean reductions of roughly 15 per cent with semaglutide and up to around 22 per cent with tirzepatide over 68 to 72 weeks, alongside lifestyle support. Individual results vary and cannot be guaranteed.
Do I keep the weight off after stopping?
Not automatically. Trial data show a significant proportion of lost weight tends to return after discontinuation, which is why these peptides are best used within a long-term metabolic plan rather than a short course.
What are the most common side effects?
Gastrointestinal effects are most common — nausea, vomiting and diarrhoea — reported by around 73 per cent of treated patients in the semaglutide label. Most are mild to moderate and ease with gradual dose titration.
Are there serious risks?
There are contraindications, including a history of medullary thyroid carcinoma, and cautions around pancreatitis and gallbladder disease. Severe dehydration from gastrointestinal effects has been linked to acute kidney injury. This is why supervision matters.
Is this only for people with a lot of weight to lose?
Suitability is assessed clinically and often relates to broader metabolic health, not weight alone. It is a medical decision made individually, not a threshold anyone can self-apply.
Can peptide therapy replace diet and exercise?
No. It is one option among several and works best alongside nutrition, physical activity and sleep. It is not a substitute for those foundations.
How are these different from the peptides used for recovery or anti-ageing?
Weight-management peptides act on metabolic and appetite pathways; cellular-repair peptides target tissue healing and recovery. They are different tools for different purposes and are assessed separately.
Can I get this treatment without a clinical assessment?
Not with us. Because of the candidacy and safety considerations, every patient begins with an individualised assessment before any recommendation is made.
Is peptide therapy for weight loss available at both Holina campuses?
Care is available at both the Koh Phangan and Khao Yai campuses in Thailand. The right pathway is determined during assessment.
I am researching this for a family member — what should I do?
The most helpful step is to encourage a proper clinical assessment, because dosing, candidacy and monitoring are individual. You are welcome to contact our team to discuss the process.
Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 20 July 2026.
